Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
NGO

Breast Cancer Now

Tracked across 2 events · 13 articles · First seen Aug 04, 2026 · Last active Sep 17, 2026

Sentiment
15
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 10
Tech
Impact: Supported the study and called for NICE to consider the findings in its guideline review, emphasizing the need for investment in family history services.
Aug 04, 2026 · 6 articles
4 20
Regulatory
The United Kingdom — National Institute for Health and Care Research (NICE) reversed its July 2024 rejection of Enhertu (trastuzumab deruxtecan) and recommended the drug for routine NHS use in Bret Engemann for around 1,000…
Impact: The charity led over two years of campaigning for Enhertu access and hailed the decision as a milestone victory while noting patients died waiting.
Sep 16, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Breast Cancer Now live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.